Article Text

Download PDFPDF

The genetics of primary open angle glaucoma
  1. Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF
  2. Department of Ophthalmology, The General Infirmary at Leeds, Belmont Grove
  3. Leeds LS2 9NS
  4. Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF
  1. Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF
  2. Department of Ophthalmology, The General Infirmary at Leeds, Belmont Grove
  3. Leeds LS2 9NS
  4. Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF
  1. Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF
  2. Department of Ophthalmology, The General Infirmary at Leeds, Belmont Grove
  3. Leeds LS2 9NS
  4. Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The advent of the discipline of molecular genetics over the past decade has led to a dramatic growth in our understanding of the genetics of a myriad of diseases. Ophthalmology has benefited greatly from this new technology, with significant advances in our knowledge about conditions as varied as aniridia and retinitis pigmentosa.1 2 Our understanding of the genetics of primary open angle glaucoma (POAG) may not be as clear as with some other ophthalmic conditions but, nevertheless, there have been great advances since the last review about the genetics of glaucoma published in the BJO in 1980.3 At that time, our knowledge was based on a number of conflicting studies attempting to link human polymorphisms, such as the ability to taste phenyl thiocarbamide, with glaucoma.4 Nowadays, the positions of genes responsible for various forms of glaucoma have been localised, not just to individual chromosomes, but to specific small regions on those chromosomes. Recently, for the first time, a gene responsible for a specific form of POAG has been identified. This review aims to highlight and explain the important recent advances in our understanding of the genetics of POAG.

    Inheritance of primary open angle glaucoma

    Primary open angle glaucoma, for the purpose of this review, refers to those cases of glaucoma in which there is not only no evident antecedent or related ocular disease but also the angle of the anterior chamber remains open at all times.5 The possibility of a genetic predisposition to glaucoma was first realised in 1842 when Benedict reported the occurrence of glaucoma in two sisters.6 Despite the intervening 150 years, our understanding of the genetics of POAG remains unclear. Certainly, most POAG pedigrees do not show a simple Mendelian pattern of inheritance. However, relatives of patients with glaucoma do run an increased risk of developing the condition compared with the general population; estimates of the increased prevalence range from 2.8% to 13.5%.7 An oligogenic, polygenic, or multifactorial mechanism is usually proposed for POAG. This assertion is supported by a number of twin studies which have shown a degree of concordance consistent with a polygenic or multifactorial inheritance.8

    A minority of POAG pedigrees do demonstrate a Mendelian pattern of inheritance. A large number of pedigrees with autosomal recessive inheritance have been described.9-11 It has been suggested that this may be the commonest type of Mendelian inheritance in POAG.12 A number of autosomal dominant pedigrees have also been described, with a degree of penetrance varying from 60% to 100%.13 14 Many of these autosomal dominant pedigrees contain members who developed glaucoma at an early age.12 13 15-20 In 1932, Bell described a large number of patients with glaucoma.21 She found that those patients with clearly inherited glaucoma tended to develop the disease before the age of 30 years. This was probably the first description of juvenile onset primary open angle glaucoma (J-POAG). J-POAG is characterised by an onset before the age of 30 (often younger), a normal cornea, high IOPs (30–50 mm Hg) with large diurnal variations, and a poor response to medical therapy, necessitating early surgical intervention.22 The appearance of the drainage angle at gonioscopy, previously thought to be normal, is in fact variable, as will be discussed.

    Autosomal dominant juvenile glaucoma can occur in association with hypoplasia of the iris.23 24 Affected individuals have characteristic slate grey or chocolate brown irides, as a result of the iris pigment epithelium showing through a hypoplastic iris stroma. An unusual type of autosomal dominant glaucoma, normal pressure glaucoma, has been described. It again tends to manifest at a fairly young age.25

    Extremely rare pedigrees showing possible sex linked inheritance have been reported. François discussed two pedigrees which he speculated could be compatible with a X linked inheritance.13 Studies concerning the association of sex with POAG have been contradictory. The Framingham study found that men were more than twice as likely as women to develop POAG, whereas the opposite was reported in a study from Sweden; no association between POAG and sex was found in Wales.26-28 These discrepancies may be due to small sample size.29

    The adjusted prevalence rate for POAG has been shown to be at least four to five times higher in blacks than whites. It is suggested that this may reflect an underlying genetic susceptibility to the disease in both adult onset primary open angle glaucoma (A-POAG) and J-POAG.29

    Traits genetically associated with primary glaucoma

    Before the advent of modern genetic techniques, much effort was invested in the investigation of traits genetically associated with POAG. This was an attempt to determine whether one or more of the commonly studied human polymorphisms, as detailed below, contributed to the polygenic aetiology of glaucoma. Carefully controlled studies were conducted in the 1960s, designed to investigate the relation between the IOP response to topical steroids and glaucoma. These studies led to the proposition that not only was the observed IOP response to topical steroids inherited, but also that the gene(s) controlling this response were also closely related to the inheritance of POAG.30-32 The proposed genetic association has since been questioned owing to a low concordance of topical steroid responsiveness in monozygotic twins and poor study reproducibility.33-35

    A close association between diabetes and POAG has been suggested on the basis of a number of studies.36 This relation however may well be multifactorial and so does not necessarily represent genetically associated traits.7

    The ability to taste phenyl thiocarbamide within the general population is thought to be genetically determined.37 Thirty per cent of the normal population are unable to taste the chemical (non-tasters). In contrast, 53% of patients with POAG have been shown to be non-tasters compared with only 17% of patients with narrow angle glaucoma, a statistically significant difference.4 This raised the possibility of a common genetic basis or even a causal interrelation. However these studies have not been consistently reproducible.38

    The research investigating the possible association between the genetically determined blood groups was conflicting. No association was reported by some studies while others suggested an increased incidence of blood group A in patients with POAG.39 40 No similar association with histocompatibility antigens was shown.41

    Overall, studies of human polymorphisms for possible association with glaucoma have given conflicting results. The validity and full significance of these studies may only be realised when the underlying molecular genetics of glaucoma are more fully understood.

    Nature versus nurture

    Does the environment play a part in the development of glaucoma? Environmental influences on the pathogenesis of glaucoma have unfortunately been little studied. It has been suggested that the season of birth is a factor in the development of POAG.42This was based on the observation that patients with POAG born in the British Isles since 1919 were significantly less likely to have been born in the 3 months from October to December, than during the remaining 9 months of the year. A similar result was found for patients born in South East Asia, but not for those born in the Caribbean. It was suggested that the observed seasonal variation may be due to a seasonal absence of certain crucial nutrients or the established seasonal variations in low birth weight.

    An exhaustive review, concentrating on the effects of lifestyle on the relative risk of developing POAG, concluded that at present little modification of lifestyle could be advised to reduce the risk of developing POAG.43 It was, however, suggested that, in appropriate patients, an aerobic exercise programme might provide a small decrease in IOP. A vegan diet, in combination with exercise, has recently been shown to result in a statistically significant reduction in IOP.44

    Molecular genetics and primary open angle glaucoma

    Utilisation of the new techniques of molecular genetics has dramatically altered the way in which we study the genetic basis of all conditions, including POAG, with a resultant rapid growth in our understanding of the subject. A plethora of techniques is now available to facilitate the identification of genes causing disease.

    The study of chromosomal abnormalities can help pinpoint a potential region in which a disease-causing gene might lie. The discovery of patients with Rieger’s syndrome with abnormalities of chromosome 4q paved the way for the establishment of linkage of the syndrome to 4q25.45 This technique has not as yet, however, provided any valuable clues as to the genetic basis of POAG.

    The candidate gene approach can be of value if a disease is thought to be caused by one or more of a limited number of known genes. This highly focused approach led to the discovery of a trinucleotide deletion in the peripherin RDS gene in autosomal dominant retinitis pigmentosa.46 Such a technique, however, is of limited value in the study of the genetics of glaucoma. This is because the number of potential causative genes is vast. A recent study looking at more than 25 candidate genes, including collagen, fibrillin, and elastin, for linkage with A-POAG found that none, in fact, were linked to the condition.47 Another study failed to demonstrate linkage between the potential candidate genes angiotensin and glucokinase, and A-POAG.48

    The technique of linkage analysis has been the most valuable tool in our attempts to unravel the genetics of POAG. The value of linkage analysis is that it can be used to localise a disease gene without any prior knowledge of the underlying pathology of the condition. Linkage analysis relies on the fact that genes which lie close to one another on a chromosome are less likely to be separated by the process of recombination during meiosis than those which lie far apart. Such genes will therefore tend to be inherited together and are described as ‘closely linked’. Recombination is the event which occurs during early meiosis, in which short lengths of chromosome are exchanged between chromosome pairs. Linkage analysis follows the co-segregation of markers of known position and the disease gene within affected pedigrees. As the position of the markers is known so the relative position of the disease gene can be established. The probability of a set of observations representing true linkage is expressed as the logarithm (to the base 10) of the odds in favour of linkage. By convention, a lod score of +3.0 (equivalent to odds of 1000:1 in favour of the loci being linked) or higher is accepted as proof of linkage, while a lod score of −2.0 (equivalent to odds of 100:1 that the loci are not linked) or lower is strong evidence against linkage. Lod scores between −2.0 and +3.0 are considered inconclusive.49 If a crossing over takes place during meiosis between the disease gene and a DNA marker it will be observed as a recombination. The importance of a recombination event is that it allows determination of a definite proximal or distal end point to the region in which the disease-causing gene lies.

    Genetics of J-POAG

    An important milestone in J-POAG genetics came from the work of Sheffield et al in 1993.50 They studied a five generation family affected by autosomal dominant J-POAG using the technique of linkage analysis. They examined 37 members of the pedigree and found that 22 were affected. More than 90 short tandem repeat polymorphisms (a type of DNA marker) distributed over the whole human genome were investigated before linkage was detected with markers from a region of the long arm of chromosome 1, 1q21-q31, with the highest lod score at site D1S212 (a DNA marker whose relative chromosomal position is known) (see Fig 1). Recombination mapping enabled the critical region to be located between markers D1S191 and D1S194, a region of 23 cM (a centiMorgan is a unit used in linkage analysis reflecting a 1% frequency of recombination and is roughly equivalent to 1 million base pairs). Subsequent linkage studies with J-POAG pedigrees has enabled a gradual narrowing of the critical region, as detailed in Table 1.50-59 The J-POAG disease gene on chromosome 1q was named GLC1A. A number of genes, known to lie within the critical region, were suggested as potential candidate genes.50 53 These included genes coding for the atrial natriuretic peptide receptor (ANPRA), laminin (LAMB2, LAMC1), and the ATPases (ATP1B1,ATPB2).60-63

    Figure 1

    Chromosome 1 and GLC1A. The approximate relative positions of DNA markers in the region 1q21-q31 are shown.

    Table 1

    A summary of previous studies with 1q21-q31 linked J-POAG pedigrees

    Earlier this year, the gene responsible for 1q linked glaucoma was identified by Stone et al.64Using a combination of fine mapping studies and mutation analysis, they identified the responsible gene as trabecular meshwork induced glucocorticoid response protein (TIGR). TIGR is produced by trabecular meshwork and ciliary body cells in response to glucocorticoids, with a timescale similar to that observed in steroid induced glaucoma.65-67 It has previously been proposed that the TIGR protein may cause increased intraocular pressure by the obstruction of aqueous outflow.68 Stone et alhave reported three mutations in the TIGR gene in chromosome 1q linked families. Two of the mutations described are missense mutations—a tyrosine to histidine change at codon 430 and a glycine to valine change at codon 357. The third is a nonsense mutation, glutamine to a stop codon at amino acid residue 361. This nonsense mutation would result in a 136 amino acid truncation of the gene product.64

    J-POAG was previously thought to show complete penetrance. More recent studies suggest that the degree of penetrance lies somewhere between 80% and 96%.69 70 Incomplete penetrance of a disease has implications for both linkage analysis and screening. Cases of reduced expressivity have also been described.71


    Phenotypic differences exist between J-POAG pedigrees which are linked to 1q21-q31.12 The pedigree described by Richardset al  53 had a mean age at diagnosis of 11.5 years, whereas the pedigrees analysed by Sheffield et al  50 had a mean age at diagnosis of 18 years. It has been suggested that the differences in the two phenotypes could have been caused by different mutations in the same gene.12 Recently, the question of genetic heterogeneity has been investigated in more detail and has been shown in fact to be related to phenotypic differences.72 From a total of nine J-POAG pedigrees, five pedigrees mapped to 1q21-q31 and four pedigrees did not. The five pedigrees which mapped to 1q21-q31 all showed uniform clinical features, including onset of the disease before the age of 20, a high IOP usually requiring surgical treatment, a high incidence of myopia, and typically a normal anterior segment structure. However, analysis of the clinical features of the four pedigrees that were not linked to the 1q21-q31 locus revealed several distinctive features. Although most showed an age of onset of less than 20 years old, several of the affected individuals did not demonstrate evidence of the disease until aged 35–40. In addition, many showed severe optic nerve degeneration yet did not exhibit the dramatic elevation in IOP seen in the five pedigrees showing linkage to 1q21-q31. Similar evidence of genetic heterogeneity has been shown in Hispanic pedigrees.73 This suggests that other, hitherto unknown, genes are also involved in the pathogenesis of J-POAG. Phenotypic expression of the gene has also been shown to be variable in two genetically identical twins who inherited the same copy of chromosome 1 from their affected father. One twin showed severe glaucoma at age 19, while the other only showed minimal glaucomatous change at the same age.74 It was suggested that it is possible that other genes or environmental factors may contribute to the full expression of J-POAG.

    Gonioscopy in J-POAG is usually described as showing no abnormalities.13 20 22 A number of papers, which demonstrate linkage of J-POAG pedigrees with 1q21-q31, commented that the drainage angles and/or trabecular meshwork appeared normal.19 50 51 However, a Danish pedigree, linked to 1q21-q31, has been described, in which gonioscopy showed various signs of goniodysgenesis—for example, high insertion of the iris, a grey membrane overlying the trabecular meshwork, and an abnormally exposed greater arterial circle of Willis, but no evidence of iris hypoplasia.56 The authors suggested that the absence of goniodysgenesis in other reported families needs to be explained. Reflecting this apparent variation in angle appearance in J-POAG, a recent study found that in 231 patients with juvenile glaucoma, 7.66% showed a closed angle and 92.34% an open angle. Of the patients with an open angle 57.34% showed no gross pathological features on gonioscopy while 35% showed goniodysgenesis.75 It has also been suggested that the trabecular meshwork is smaller in eyes with J-POAG compared with normal eyes.76

    The discovery of individuals with J-POAG and individuals with A-POAG both within the same pedigree, as discussed below, suggests the presence of phenotypic heterogeneity—that is, a mutation of one gene giving rise to more than one phenotype.55

    Studies of pedigrees with iris hypoplasia in addition to juvenile/early onset autosomal dominant glaucoma, similar to those previously described by other authors,23 24 have failed to show linkage to 1q21-q31, suggesting a genetic as well as phenotypic difference.56 77 Recently, two autosomal dominant pedigrees with features of iris hypoplasia, goniodysgenesis, and juvenile glaucoma, termed the iridogoniodysgenesis anomaly, were mapped to an 8.3 cM region on chromosome 6, 6p25.78 A distinct syndromic form of iridogoniodysgenesis, with non-ocular features including jaw and dental abnormalities, has been mapped to 4q25, the same locus as that suggested for Rieger’s syndrome.45 79

    Genetics of A-POAG

    Possible involvement of the 1q region in the pathogenesis of A-POAG was suggested by the discovery of a weak association between A-POAG and the Duffy blood group,80 which was later shown to be coded for by the FY gene located in the region 1q22-q23.81 A number of subsequent studies, however, failed to demonstrate linkage between A-POAG pedigrees and 1q21-q31.52 82-86

    This apparent genotypic chasm between A-POAG and J-POAG was potentially bridged by the recent work of Morissette et al.55 They studied 142 members of a huge seven generation French Canadian pedigree traced back to a single affected male born in 1799. Thirty six patients were found to have J-POAG (median age at diagnosis of 27.3 years), while four individuals were found to have A-POAG (age of onset older than 40 years). Six members were diagnosed as having ocular hypertension. Linkage analysis and recombination mapping showed that not only the patients with J-POAG but also those with A-POAG and those with ocular hypertension were all tightly linked to the region 1q21-q31. The maximum lod score of 6.62 occurred with the marker AFM278ye5 (see Fig 1). The authors concluded that these results demonstrated that the same glaucoma gene is responsible for both A-POAG and J-POAG. They suggested that the J-POAG and A-POAG categories within this family may in fact be part of a clinical continuum artificially divided at 40 years. The same group have since looked at another 52 family members and report similar findings.87 The relevance of these findings to other pedigrees and affected individuals needs to be examined. The patients defined as having J-POAG in this study differed significantly from many other reported pedigrees: the average age of onset was at least 10 years older and IOPs at the time of diagnosis were usually in the 25–30 mm Hg range, which is about 10–15 mm Hg below that observed in other J-POAG families. Morissette et al suggested that the differences between the J-POAG phenotypes in their study and the J-POAG phenotypes described in other linkage studies may be explained by the presence of a different mutation in either the same or a closely related gene. It has since been argued that the phenotype described in their paper is an example of the variable expression of the J-POAG phenotype rather than true A-POAG.88 It is asserted that onset before age 40 years is an arbitrarily defined distinction between the two forms of the disease. In addition, the possibility exists that the four individuals classified as having A-POAG had in fact developed the disease before the age of 40 years. Despite these reservations the findings of their study are of great potential significance. Similar results have since been shown for a French pedigree in which both J-POAG and early onset A-POAG individuals showed linkage to theGLC1A interval.58

    Strong evidence for the involvement of GLC1A in primary open angle glaucomas other than J-POAG, comes from the recent identification of TIGR by Stone et al.64 In addition to finding mutations in TIGR in chromosome 1q linked glaucoma families, the same TIGR mutations have also been shown, not only in adult onset glaucoma patients with a family history of the disease, but also in 2.9% unrelated consecutively ascertained patients from a general glaucoma clinic. They suggested that this indicates that TIGR is involved in a significant fraction of all glaucomas, rather than just in J-POAG or those cases in which there is a strong family history. Estimates suggest that mutations in the TIGR gene may cause glaucoma in up to 100 000 individuals in the USA.

    Identification of the role of TIGR in POAG may explain the previously recognised relation between the IOP response to glucocorticoids and glaucoma.30-32

    The 1q21-q31 region has been excluded from involvement in the genetics of primary congenital glaucoma and the pigment dispersion syndrome.89 90

    A locus for A-POAG on chromosome 2, 2cen-q13, has been described.91 It comprises an 11.2 cM region between markers D2S2161 and D2S176. Affected individuals, from the six linked pedigrees, all exhibited similar clinical features. Fifty per cent of the affected subjects had a highest recorded IOP of less than 22 mm Hg, while the remaining individuals, bar one, showed only moderate highest recorded IOPs of 22–30 mm Hg. Onset occurred in the late forties and there was usually a good response to medical treatment. Thus, this locus, termed GLC1B, seems to be possibly implicated in the pathogenesis of low or normal tension glaucoma, as well as those cases of A-POAG in which one sees only a modest rise in IOP. A number of genes are known within the 2cen-q13 region, but none have been suggested as obvious candidate genes. Eight additional pedigrees in this study did not show linkage with the GLC1B locus. These pedigrees differed from the linked pedigrees in that they showed more significant maximum rises in IOP.

    A locus for A-POAG has also recently been described on chromosome 3, 3q21-q24.92 Twelve affected individuals, all members of a single autosomal dominant A-POAG pedigree, were shown to be linked to an 11.1 cM region on chromosome 3q, between markers D3S3637 and D3S1744. This gene has been termed GLC1C.

    The future

    Identification of not only the GLC1A gene, but also other future glaucoma genes, has enormous potential clinical and commercial consequences. It should allow a significant advance in our understanding of the pathophysiology of POAG. It still remains to be established whether mutations in the TIGR gene result in an obstruction of aqueous humour outflow through the trabecular meshwork, as is seen in the presence of high levels of the TIGR protein.93 To this end, Stone’s and Sheffield’s groups are now trying to develop genetically engineered mice, some of which produce the mutated form of the TIGR protein, and some which do not produce any TIGR protein. With an increased understanding of the underlying pathology of glaucoma, it may be possible to develop novel treatments for glaucoma, targeted at the root cause of the condition, as opposed to the currently available rather empirical treatments. Inexpensive and accurate screening of at risk individuals, before they show any manifestations of glaucoma, should become possible. Indeed, encouraging early studies to evaluate J-POAG screening had already been conducted before the identification ofGLC1A.69 70 Gene therapy is concerned with treating genetic disease at the molecular level and can involve correction, replacement, or augmentation of the functional gene. It has been suggested that treatment of glaucoma by gene therapy is a distant possibility.94 Discovery of the differing genetic causes of POAG and glaucoma in general may lead to an improved classification of the condition based on the precise causative genetic mutation rather than the current rather vague clinical classification. A similar genetic reclassification of a clinically confusing condition has already occurred to some extent with retinitis pigmentosa.2 95

    Progress in the identification of other glaucoma genes, such asGLC1B and GLC1C, will depend largely on the identification of new pedigrees linked to chromosomes 2 and 3. This should enable the identification of critical recombinants, so allowing further narrowing of the regions in which GLC1B andGLC1C are known to lie. Likewise, the discovery of new loci involved in glaucoma also relies on the study of further glaucoma pedigrees. It would, therefore, be of enormous benefit if clinicians could refer potential pedigrees to an appropriate centre for further genetic investigation. Similarly, identification of POAG patients who demonstrate chromosomal rearrangements would be of tremendous help. It is only through this partnership of molecular genetics and clinical ophthalmology that these important genes will be found. The development of new polymorphic markers within the critical regions will also play a part in enabling localisation of these genes. Once the location of a gene has been narrowed to a region of approximately 1 cM, physical mapping techniques can be used in an attempt to identify the gene. Once identified, putative genes can be sequenced and analysed for mutations segregating with affected individuals.

    The repertoire of new techniques and ideas in molecular biology is expanding at an ever increasing rate. The impending completion of the Human Genome Mapping Project will increase the pace of advance even further. It is vital that clinical ophthalmology remains in touch with these exciting discoveries. The third millennium may then herald the arrival of radical new approaches to the diagnosis and management of glaucoma.


    This work was funded by the Medical Research Council and the Northern and Yorkshire Regional Health Authority. Additional support for the authors’ laboratory is provided by the Wellcome Trust, Yorkshire Cancer Research Campaign, and the West Riding Medical Research Trust.


    View Abstract